Transthyretin Cardiac Amyloidosis in HFpEF
Completed · Early Phase 1
Conditions studied: Heart Failure With Preserved Ejection Fraction
In brief
To estimate the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among Heart Failure with Preserved Ejection Fraction (HFpEF) patients with increased LV wall thickness in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/CT).
Key facts
- Study ID
- NCT03414632
- Run by
- Mayo Clinic
- People needed
- 287
- Starts
- 2017-12-01
- Expected to finish
- 2020-03-31
- Last updated by the study team
- 2021-03-19
Who can join
Age: 60 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Resident of Southeastern Minnesota (Olmsted, Dodge, Fillmore, Mower, Freeborn, Wabasha, or Steele County)
- Current diagnosis of HF per NLP search
- Age > 60 years
- Clinically obtained echocardiogram within 12 months of index visit showing:
- EF ≥ 40% and
- Increased Left Ventricular (LV) wall thickness as defined by an end-diastolic left ventricular septal or posterior wall thickness (LVWTd) ≥ 20% above the upper limit of normal measured by 2D or M-mode imaging in the parasternal long (2D) or short (M-mode) axis view (≥12 mm).
- Objective evidence of HF defined as one or more of the following present within 24 months of index visit:
- Meet Framingham Criteria at index visit (In-patient or outpatient)
- Previous HF hospitalization
- Invasive hemodynamic documentation of elevated pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) (> 18 mmHg at rest or > 25 mmHg with exercise)
- Left atrial enlargement + loop diuretic for HF(clinically obtained) N-terminal pro b-type natriuretic peptide (NT-proBNP) > 300 (sinus rhythm) or >900 (atrial fibrillation) pg/mL
You may not qualify if…
- Documentation of previous EF < 40%
- Any cardiac surgery or major chest trauma within 4 weeks of index visit
- Presence or history of hemodynamically significant left sided valvular disease defined as:
- Greater than mild mitral stenosis
- Intrinsic mitral valve disease (prolapse, flail) with greater than moderate regurgitation
- Myocardial infarction within 4 weeks of index visit defined by typical angina, EKG changes and significant change in serial troponins. Note that chronic troponin elevation is extremely common in cardiac amyloidosis. Hospitalized patients with troponin elevation but no significant change (delta) on serial testing will NOT be excluded.
- Prior or current exposure to Plaquenil (Hydroxychloroquine)
Where it is running
- Mayo Clinic in Rochester — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.